Achondroplasia
Conditions
Keywords
Skeletal dysplasia, Endochondral ossification, ACH, Shortened proximal limbs, Fibroblast growth factor receptor 3, FGFR3, Endochondral bone formation, Short-limb disproportionate dwarfism, dwarfism, Bone disease, Bone diseases, developmental, Musculoskeletal diseases, Osteochondrodysplasia, Genetic diseases, inborn, Inborn
Brief summary
This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK Substudy to fully characterize the pharmacokinetics of infigratinib in children with ACH.
Interventions
DRUGInfigratinib 0.016 mg/kg
Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
DRUGInfigratinib 0.032 mg/kg
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
DRUGInfigratinib 0.064 mg/kg
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
DRUGInfigratinib 0.128 mg/kg
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
DRUGInfigratinib 0.25 mg/kg
Subsequent cohort dose escalation based on protocol-specific criteria. Infigratinib tablets to be administered by mouth.
Sponsors
QED Therapeutics, a BridgeBio company
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 11 Years
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent by participant or parent(s) or legally authorized representative (LAR) and signed informed assent by the participant (when applicable). 2. Diagnosis of ACH, documented clinically and confirmed by genetic testing. 3. At least a 6-month period of growth assessment in the PROPEL study (Protocol QBGJ398-001) before study entry. 4. Ambulatory and able to stand without assistance 5. Able to swallow oral medication.
Exclusion criteria
1. Hypochondroplasia or short stature condition other than ACH. 2. In females, having had their menarche. 3. Height \< -2 or \> +2 standard deviations for age and sex based on reference tables on growth in children with ACH. 4. Significant concurrent disease or condition that, in the view of the Investigator and/or Sponsor, would confound assessment of efficacy or safety of infigratinib. 5. Current evidence of corneal or retinal disorder/keratopathy. 6. History of malignancy. 7. Currently receiving treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration. 8. Treatment with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the previous 6 months or long-term treatment (\>3 months) at any time. 9. Treatment with a C-type natriuretic peptide (CNP) analog, fibroblast growth factor (FGF) ligand trap, or treatment targeting FGFR inhibition at any time. 10. Regular long-term treatment (\>3 weeks) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable). 11. Treatment with any other investigational product or investigational medical device for the treatment of ACH or short stature. 12. Previous limb-lengthening surgery or guided growth surgery. 13. Fracture within 12 months of screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of treatment-emergent adverse events (TEAEs) that lead to dose decrease or discontinuation | Up to 18 months |
| Change from baseline in annualized height velocity | Up to 18 months |
| PK parameters of infigratinib (Cmax- PK substudy only) | 21 days |
| PK parameters of infigratinib (Clast- PK substudy only) | 21 days |
| PK parameters of infigratinib (Tmax- PK substudy only) | 21 days |
| PK parameters of infigratinib (AUC24- PK substudy only) | 21 days |
| PK parameters of infigratinib (T1/2- PK substudy only) | 21 days |
| PK parameters of infigratinib (AUCinf- PK substudy only) | 21 days |
| PK parameters of infigratinib (CL/F- PK substudy only) | 21 days |
| PK parameters of infigratinib (Vz/F- PK substudy only) | 21 days |
| PK parameters of infigratinib (Racc- PK substudy only) | 21 days |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability | Up to 18 months |
| Changes in pharmacodynamic parameters by assessing collagen X marker | Up to 18 months |
| Absolute height velocity (annualized to cm/year), expressed numerically and as Z-score in relation to ACH and non-ACH tables | Up to 18 months |
| Absolute and change from baseline in weight (kg) | Up to 18 months |
| Absolute and change from baseline in sitting height (cm) | Up to 18 months |
| Absolute and change from baseline in head circumference (cm) | Up to 18 months |
| Absolute and change from baseline in upper and lower arm length (cm) | Up to 18 months |
| Absolute and change from baseline in thigh length (cm) | Up to 18 months |
| Absolute and change from baseline in knee height (cm) | Up to 18 months |
| Absolute and change from baseline in arm span (cm) | Up to 18 months |
| Pharmacokinetic profile of infigratinib by assessment of maximum concentration (Cmax) | Up to 18 months |
| Pharmacokinetic profile of infigratinib by assessment of time-to-maximum concentration (Tmax) | Up to 18 months |
Countries
Australia, Canada, France, Spain, United Kingdom, United States
Outcome results
None listed